rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PTCT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PTC Therapeutics at Jefferies Global Healthcare Conference: growth broadens
      Nov 16Investing.comPTCTJEF
      Why is PTC Therapeutics stock surging today?
      Nov 3Investing.comPTCT
      PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows (NASDAQ:PTCT)
      Nov 3Seeking AlphaPTCT
      PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
      Nov 3Yahoo FinancePTCT
      PTC Therapeutics to Participate in Upcoming Investor Conferences

      PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

      Nov 2Yahoo FinancePTCT
      Truist reiterates Hold on PTC Therapeutics stock after Q3 results
      Nov 2Investing.comPTCTTFC
      PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss
      Oct 31Yahoo FinancePTCT
      Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and PTC Therapeutics (PTCT)

      Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

      Oct 31The Globe and MailPTCTBSX
      PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In Focus

      PTC Therapeutics (PTCT) is back in focus after its third quarter, when revenue of US$357.81 million topped analyst forecasts and management lifted full year sales guidance for 2026. Despite the upbeat third quarter and higher 2026 revenue guidance, PTC Therapeutics’ share price has slipped, with a 1-month share price return of down 7.43% and a year to date share price return of down 21.85%. At the same time, the 3-year total shareholder return is up about 3x and the 5-year total shareholder...

      Oct 30Yahoo FinancePTCT
      PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

      Oct 30Yahoo FinancePTCT
      PTC Therapeutics' Sephience Drug to Grow at Steady Pace With International Expansion, RBC Says
      Oct 30Yahoo FinancePTCT
      PTC Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinancePTCT
      RBC Raises Price Target on PTC Therapeutics to $77 From $75, Keeps Sector Perform Rating
      Oct 30Yahoo FinancePTCT
      PTC Therapeutics Inc (PTCT) Q3 2026 Earnings Call Highlights: Record Revenue, Raised Guidance ...
      Oct 30Yahoo FinancePTCT
      PTC Therapeutics Q3 Earnings Call Highlights
      Oct 30Yahoo FinancePTCT
      Earnings call transcript: PTC Therapeutics tops revenue forecasts in Q3 2026
      Oct 29Investing.comPTCT
      PTC Therapeutics Q3 2026 Earnings Call Transcript
      Oct 29BenzingaPTCT
      PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Oct 29Yahoo FinancePTCT
      PTC Therapeutics earnings missed by $0.92, revenue topped estimates
      Oct 29Investing.comPTCT
      PTC Therapeutics Swings to Q3 Loss, Revenue Rises; Increases 2026 Outlook
      Oct 29Yahoo FinancePTCT
      PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
      Oct 29Yahoo FinancePTCPTCT
      PTC Therapeutics: Q3 Earnings Snapshot
      Oct 29Yahoo FinancePTCPTCT
      PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
      Oct 29Yahoo FinancePTCT
      Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

      PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 22Yahoo FinancePTCT
      PTC Therapeutics director sells $149,036 in shares
      Oct 17Investing.comPTCT
      UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating
      Oct 15Yahoo FinancePTCT
      PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

      PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.

      Oct 15Yahoo FinancePTCT
      PTC Therapeutics CLO Mark Boulding sells $12,337 in stock
      Oct 14Investing.comPTCT
      Ptc Therapeutics stock hits 52-week low at $61.20
      Oct 13Investing.comPTCT
      PTC Therapeutics director Glenn Steele sells $781,920 in shares
      Oct 13Investing.comPTCT
      PTC Therapeutics director Michael Schmertzler sells $158k in shares
      Oct 9Investing.comPTCT
      PTC Therapeutics (PTCT) Gets a Hold from RBC Capital

      Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailPTCT
      RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating
      Oct 8Yahoo FinancePTCT
      PTC Therapeutics CLO Mark Boulding sells $132,790 in shares
      Oct 7Investing.comPTCT
      PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says
      Oct 7Yahoo FinancePTCT
      RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform
      Oct 7Investing.comPTCT
      PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 25Yahoo FinancePTCT
      Cantor raises PTC Therapeutics stock price target on Fabry deal
      Sep 22Investing.comPTCT
      PTC Therapeutics completes ST-920 gene therapy acquisition
      Sep 21Investing.comPTCT
      PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

      PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for

      Sep 21Yahoo FinancePTCT
      PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

      PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

      Sep 21Yahoo FinancePTCT
      PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

      PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...

      Sep 20Yahoo FinancePTCT
      PTC Therapeutics director Schmertzler sells $1.35m shares
      Sep 19Investing.comPTCT
      PTC Therapeutics at Morgan Stanley conference: sephience drives outlook
      Sep 15Investing.comPTCTMS
      PTC Therapeutics director Schmertzler sells $1.35m in stock
      Sep 12Investing.comPTCT
      PTC Therapeutics at cantor healthcare conference: sephience drives growth
      Sep 11Investing.comPTCT
      PTC Therapeutics at Wells Fargo conference: sufiance drives growth plan
      Sep 10Investing.comPTCTWFC
      Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

      Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailPTCT
      PTC Therapeutics director Michael Schmertzler sells $1.8m in shares
      Aug 29Investing.comPTCT
      PTC Therapeutics to Participate in Upcoming Investor Conferences

      PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

      Aug 27Yahoo FinancePTCT

      This is the newest page. Registered accounts read further back.